Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Finished Goods (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Finished Goods data on record, last reported at $18.6 million in Q4 2025.

  • For Q4 2025, Finished Goods fell 19.46% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $18.6 million, down 19.46%, while the annual FY2025 figure was $18.6 million, 19.46% down from the prior year.
  • Finished Goods reached $18.6 million in Q4 2025 per MRVI's latest filing, down from $19.6 million in the prior quarter.
  • Across five years, Finished Goods topped out at $23.1 million in Q4 2024 and bottomed at $6.3 million in Q2 2021.
  • Average Finished Goods over 5 years is $14.6 million, with a median of $12.9 million recorded in 2021.
  • Peak YoY movement for Finished Goods: decreased 26.16% in 2022, then soared 185.77% in 2024.
  • A 5-year view of Finished Goods shows it stood at $10.4 million in 2021, then decreased by 26.16% to $7.7 million in 2022, then skyrocketed by 151.15% to $19.4 million in 2023, then rose by 18.98% to $23.1 million in 2024, then decreased by 19.46% to $18.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $18.6 million in Q4 2025, $19.6 million in Q3 2025, and $19.7 million in Q2 2025.